See more : King Gen Public Company Limited (KGEN.BK) Income Statement Analysis – Financial Results
Complete financial analysis of X4 Pharmaceuticals, Inc. (XFOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of X4 Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Svenska Nyttobostäder AB (publ) (NYTTO-PREF.ST) Income Statement Analysis – Financial Results
- Probe Gold Inc. (V46.F) Income Statement Analysis – Financial Results
- Wells Fargo & Company (WFC.SW) Income Statement Analysis – Financial Results
- Nevaro Capital Corporation (NVPLF) Income Statement Analysis – Financial Results
- Gores Technology Partners II, Inc. (GTPBU) Income Statement Analysis – Financial Results
X4 Pharmaceuticals, Inc. (XFOR)
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 3.00M | 0.00 | 3.50M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.00M | 1.99M | 1.89M | 0.00 | 672.00K | 103.00K | 195.00K | 300.00K | 400.00K |
| Gross Profit | -2.00M | -1.99M | -1.89M | 3.00M | -672.00K | 3.40M | -195.00K | -300.00K | -400.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 97.06% | 0.00% | 0.00% | 0.00% |
| Research & Development | 72.02M | 61.06M | 50.65M | 41.93M | 30.16M | 30.98M | 28.13M | 17.83M | 12.71M |
| General & Administrative | 0.00 | 0.00 | 24.70M | 20.94M | 17.64M | 18.41M | 8.01M | 6.52M | 2.12M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.51M | 27.02M | 24.70M | 20.94M | 17.64M | 18.41M | 8.01M | 6.52M | 2.12M |
| Other Expenses | 0.00 | -6.27M | -3.57M | -2.11M | -1.10M | -85.00K | -16.00K | 104.00K | -77.00K |
| Operating Expenses | 107.52M | 88.08M | 75.35M | 62.87M | 47.80M | 46.21M | 32.27M | 21.96M | 12.67M |
| Cost & Expenses | 107.52M | 88.08M | 75.35M | 62.87M | 47.80M | 46.21M | 32.27M | 21.96M | 12.67M |
| Interest Income | 4.58M | 219.00K | 10.00K | 273.00K | 1.20M | 809.00K | 214.00K | 0.00 | 0.00 |
| Interest Expense | 5.78M | 3.99M | 3.64M | 2.69M | 2.15M | 1.04M | 2.08M | 2.52M | 472.00K |
| Depreciation & Amortization | 419.00K | 1.99M | 1.89M | 1.23M | 672.00K | 103.00K | 195.00K | 300.00K | 389.00K |
| EBITDA | -107.52M | -87.57M | -85.11M | -58.07M | -51.70M | -45.89M | -31.60M | -20.16M | -12.35M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,995.80% | 0.00% | -1,195.06% | 0.00% | 0.00% | 0.00% |
| Operating Income | -107.52M | -87.57M | -85.11M | -59.87M | -51.70M | -45.89M | -36.13M | -24.35M | -14.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,995.80% | 0.00% | -1,311.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.43M | -6.27M | -3.57M | -2.11M | -1.10M | 2.86M | 2.26M | 6.48M | 1.61M |
| Income Before Tax | -101.09M | -93.84M | -88.68M | -61.98M | -52.81M | -43.02M | -33.88M | -22.98M | -13.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -2,066.10% | 0.00% | -1,229.17% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 78.00K | 28.00K | 17.00K | 148.00K | 3.80M | 3.90M | 1.87M | 2.62M | 395.00K |
| Net Income | -101.17M | -93.87M | -88.70M | -62.13M | -56.60M | -43.02M | -33.88M | -22.98M | -13.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -2,071.03% | 0.00% | -1,229.17% | 0.00% | 0.00% | 0.00% |
| EPS | -0.57 | -1.48 | -3.44 | -3.09 | -4.91 | -93.73 | -98.58 | -24.76 | -14.24 |
| EPS Diluted | -0.57 | -1.48 | -3.44 | -3.09 | -4.91 | -93.73 | -98.58 | -24.76 | -14.24 |
| Weighted Avg Shares Out | 177.81M | 63.53M | 25.75M | 20.08M | 11.53M | 459.00K | 343.64K | 928.01K | 928.01K |
| Weighted Avg Shares Out (Dil) | 177.81M | 63.53M | 25.75M | 20.08M | 11.53M | 459.00K | 343.64K | 928.01K | 928.01K |
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on September 29, 2023, the company issued inducement awards...
X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the...
X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the...
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
Submission supported by positive results from global, pivotal 4WHIM Phase 3 clinical trial Submission supported by positive results from global, pivotal 4WHIM Phase 3 clinical trial
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced that, effective on August 31, 2023,...
X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market
X4 is nearing approval of its lead candidate for WHIM syndrome and aims for label expansion to a much larger market of chronic neutropenias. Despite very small WHIM target population, orphan designation (=premium pricing) and potential for non-dilutive funding from...
X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program
Submission of first U.S. New Drug Application for mavorixafor in WHIM syndrome on track for early 2H 2023 Emerging data from ongoing Phase 2 trial in certain chronic neutropenic disorders show mavorixafor durably increased neutrophil counts and enabled reductions in...
X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer
BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that Christophe Arbet-Engels, MD, PhD,...
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million...
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting...
Source: https://incomestatements.info
Category: Stock Reports
What is the projected cash runway for X4 Pharmaceuticals?
X4 Pharmaceuticals Inc (NASDAQ:XFOR) ended the third quarter of 2024 with cash and equivalents of almost $136 million, providing a financial runway into late 2025.
What were X4 Pharmaceuticals’ net revenues in Q3 2024?
Revenue and Cost of Revenue: For the three months ended September 30, 2024 , X4 reported net product revenue of $0.6 million and cost of revenue of $0.2 million related to the sale of XOLREMDI.